ストックスクリーナーアプリを入手
10.75
2.63%
-0.2797
前日終値:
$11.03
開ける：
$11.09
24時間の取引高:
141.07K
Relative Volume:
0.17
時価総額：
$564.06M
収益：
$1.02B
当期純損益:
$-757.20M
株価収益率:
-0.7283
EPS:
-14.76
ネットキャッシュフロー:
$-257.90M
1週間 パフォーマンス:
+1.90%
1か月 パフォーマンス:
-13.32%
6か月 パフォーマンス:
+20.54%
1年 パフォーマンス:
+13.41%
1日の値動き範囲:
$10.67
$11.12
1週間の範囲:
$10.40
$11.45
52週間の値動き範囲:
$4.02
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
名前
Emergent Biosolutions Inc
セクター
電話
240-631-3200
住所
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.74 | 579.30M | 1.02B | -757.20M | -257.90M | -14.76 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.34 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.31 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.18 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.94 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.32 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-22 | 開始されました | Rodman & Renshaw | Buy |
| 2024-03-07 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Underweight |
| 2023-08-29 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-04-10 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-10 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-04-29 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-11-08 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-05-05 | ダウングレード | Argus | Buy → Hold |
| 2021-04-07 | 開始されました | The Benchmark Company | Buy |
| 2021-02-24 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 再開されました | JP Morgan | Neutral |
| 2020-07-31 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
| 2019-09-04 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | アップグレード | Goldman | Neutral → Buy |
| 2018-08-03 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-06-13 | 開始されました | Argus | Buy |
| 2018-04-25 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2018-01-16 | 繰り返されました | Chardan Capital Markets | Buy |
| 2016-06-28 | 繰り返されました | Singular Research | Buy |
| 2016-04-15 | 開始されました | Chardan Capital Markets | Buy |
| 2016-03-28 | 開始されました | Singular Research | Buy |
| 2016-02-19 | 開始されました | Wells Fargo | Outperform |
| 2014-05-15 | 開始されました | Summer Street Research | Buy |
| 2011-05-31 | 繰り返されました | WBB Securities | Strong Buy |
| 2011-01-10 | 繰り返されました | Wedbush | Outperform |
| 2010-11-05 | 繰り返されました | Wedbush | Outperform |
| 2010-08-18 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 繰り返されました | Caris & Company | Buy |
すべてを表示
Emergent Biosolutions Inc (EBS) 最新ニュース
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Emergent Biosolutions Inc. $EBS Shares Purchased by Allianz Asset Management GmbH - MarketBeat
How strong dollar benefits Emergent BioSolutions Inc. stockJuly 2025 Snapshot & Capital Efficient Trade Techniques - mfd.ru
New York State Common Retirement Fund Has $4.60 Million Stock Holdings in Emergent Biosolutions Inc. $EBS - MarketBeat
How Emergent Biosolutions Inc. (EBS) Affects Rotational Strategy Timing - Stock Traders Daily
NYAG's Insider Trading Case A Power Grab, Judge Told - Law360
Retail Surge: Can Emergent BioSolutions Inc stock outperform in a bear marketPortfolio Value Summary & Free Community Consensus Stock Picks - baoquankhu1.vn
Federated Hermes Inc. Raises Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent BioSolutions Inc. (EBS) Stock Analysis: Evaluating a 13.45% Upside Potential Amidst Sector Challenges - DirectorsTalk Interviews
Emergent Biosolutions (NYSE:EBS) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Why is Emergent BioSolutions Inc stock going downJuly 2025 Market Mood & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Market Review: Is Emergent BioSolutions Inc stock showing strong momentumWeekly Stock Analysis & Daily Entry Point Alerts - baoquankhu1.vn
Lipid Nanoparticle Manufacturing Market: An 18.9% CAGR Market Driven by Nucleic Acid Therapies - GlobeNewswire Inc.
Emergent BioSolutions Inc. (EBS) Stock Analysis: Is The 11.66% Upside Worth The Risk? - DirectorsTalk Interviews
Emergent Biosolutions (NYSE:EBS) Share Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Biotech Co. Gets OK For $10M Stalking Horse Bid - Law360
Emergent BioSolutions (EBS) receives a new order from US Department of War - MSN
Bispecific Antibody Market with Insights from Immunomedics, - openPR.com
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing - FinancialContent
Former biotech CEO sued over COVID vaccine alleged insider trading - AOL.com
Moving Averages: Will Norfolk Southern Corporation outperform tech stocksJuly 2025 Catalysts & Safe Entry Trade Signal Reports - baoquankhu1.vn
Ex-Biotech CEO Cashed In $10M Ahead Of COVID Vaccine Crisis: Lawsuit - AOL.com
JPM movers: ImmunityBio rises to the top - BioCentury
FRAUD AND MANIPULATION—N.Y. Sup.: New York’s AG sues former Emergent BioSolutions CEO for insider trading - VitalLaw.com
Insider Sell: Can BOS Better Online Solutions Ltd disrupt its industryPortfolio Value Summary & AI Driven Price Forecasts - baoquankhu1.vn
Retail Trends: Is CMREPRC stock technically oversoldEarnings Trend Report & Daily Price Action Insights - baoquankhu1.vn
Lobbying Update: $430,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Quiver Quantitative
New York Sues Former C.E.O. of Covid Vaccine Maker Over Insider Trading - The New York Times
Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading - BioPharma Dive
Emergent BioSolutions (EBS) Receives a New Order from US Department of War - Insider Monkey
Emergent BioSolutions (EBS) Sued for Insider Trading, Agrees to $900K Settlement - Intellectia AI
Read This Before Judging Emergent BioSolutions Inc.'s (NYSE:EBS) ROE - Yahoo Finance
Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 23% Upside Potential and Robust Free Cash Flow - DirectorsTalk Interviews
Ex-CEO sued by New York for insider trading tied to COVID-19 vaccine contamination - whtc.com
New Packaging Option for Narcan Nasal Spray Aims to Reduce Stigma - Psychiatry Advisor
Ex-CEO Of COVID Vax Maker Accused Of Insider Trading - Law360
Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO - Stocktwits
NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading - The Wall Street Journal
Ex-CEO sued by New York for insider trading tied to COVID vaccine contamination - Reuters
NY Sues Ex-Emergent BioSolutions CEO for Insider Trading (1) - Bloomberg Law News
Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4%What's Next? - MarketBeat
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update - marketscreener.com
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading - marketscreener.com
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
Investors five-year losses continue as Emergent BioSolutions (NYSE:EBS) dips a further 7.5% this week, earnings continue to decline - Sahm
Emergent BioSolutions makes $100 million voluntary loan prepayment By Investing.com - Investing.com Nigeria
Emergent Biosolutions' Former CEO Sued for Insider Trading, Facing $900,000 Penalty - Intellectia AI
Emergent BioSolutions Inc CEO Presents at J.P. Morgan Healthcare Conference - TradingView
Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet? - 富途牛牛
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness - The Manila Times
Emergent Biosolutions Receives U.S. FDA Approval On Supplemental New Drug Application For Narcan® Nasal Spray To Be Packaged In A New Carrying Case, Making Life-Saving Naloxone More Accessible For Everyday Preparedness - TradingView
Emergent Biosolutions Inc (EBS) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
8.56%
大文字化:
|
ボリューム (24 時間):